The potential remains. From one drop of blood, medical professionals could run dozens of tests and glean results in a matter of minutes.
San Diego-based Genalyte was making this a reality long before Theranos burst onto the scene. And with $36 million in new funding — the round was led by Khosla Ventures and Redmile Group — they’ll likely outlive the field’s infamous and now-crippled unicorn.
